Your session is about to expire
← Back to Search
CapTem + Y90 for Neuroendocrine Cancer (CapTemY90 Trial)
CapTemY90 Trial Summary
This trial is testing if a combination of two treatments is more effective than either treatment alone in preventing the progression of liver metastases in patients with neuroendocrine tumors.
CapTemY90 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCapTemY90 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CapTemY90 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Less than half of my liver is affected by cancer.I have a grade 2 neuroendocrine tumor with liver metastases that cannot be surgically removed.My liver is working well, based on recent tests.My blood platelets, kidney function, and blood clotting levels are within the required ranges.I cannot take capecitabine or temozolomide due to adverse reactions.It has been over 4 weeks since my last chemo or radiation treatment.I cannot have a specific liver cancer treatment due to high risk of complications.I cannot have IV contrast due to a severe past reaction.My main portal vein is open and unblocked.I am older than 18 years.I have had surgery or a procedure to treat bile duct blockage.I am using effective birth control or have confirmed I am not pregnant.Half or more of my cancer is in my liver.I have had treatment with transarterial embolization or radioembolization.I do not have any serious illnesses or social situations that would stop me from following the study's requirements.I can take care of myself and am up and about more than half of the day.I have a liver tumor larger than 1cm that can be measured.
- Group 1: Oral CapTem + Y90 Radioembolization
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What medical applications does transarterial radioembolization typically target?
"Transarterial radioembolization is the favoured treatment method for progressive disease. This therapy can also be applied to other medical conditions including nitrosourea-resistant cancers, end of life planning, and refractory cases of mycosis fungoides."
What risks are associated with transarterial radioembolization?
"Considering the Phase 2 label, which suggests that there is only limited efficacy data available, transarterial radioembolization was assigned a score of 2 for safety."
What is the uppermost threshold of participants in this experiment?
"This medical trial requires 50 suitable participants, and patient recruitment is occurring at the University of Pennsylvania in Philadelphia and CARTI Cancer Center in Little Rock."
Is this research recruitment still open?
"Affirmative. Clinicaltrials.gov's information demonstrates that the study is presently searching for participants, with a commencement date of October 7th 2021 and most recent update occurring on August 11 2022. The medical trial requires 50 patients from 3 different healthcare facilities."
Is this a groundbreaking trial that has never been seen before?
"Since the initial 2002 trial sponsored by Schering-Plough and featuring 60 patients, transarterial radioembolization has been studied extensively. Currently, there are 531 ongoing trials for this procedure located in 2291 cities over 70 countries worldwide which have seen it receive Phase 2 drug approval."
What precedent has been set by other research projects utilizing transarterial radioembolization?
"Transarterial radioembolization was trialled for the first time in 2002 at Memorial Sloan Kettering Cancer Center, with 844 trials having since been completed. Currently 531 active studies are recruiting patients, and a vast proportion of these are situated within Philadelphia, Pennsylvania."
Share this study with friends
Copy Link
Messenger